Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590400 | 0.96 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL1590116 | 0.95 | AKR1C3 (0.40) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL1591540 | 0.93 | PTGER4 (0.39) | AKR1C3AKR1C2PTGER4CYP1A2CYP2D6 | |
| SCHEMBL1590574 | 0.92 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL2299558 | 0.89 | PTGER4 (0.48) | AKR1C3AKR1C2PTGER4PTGS1CYP1A2 | |
| SCHEMBL1589945 | 0.88 | PTGER4 (0.45) | AKR1C3AKR1C2PTGER4PTGS1CYP1A2 | |
| SCHEMBL2299042 | 0.87 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL1591360 | 0.86 | PTGER4 (0.42) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL1591384 | 0.86 | AKR1C3 (0.39) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 | |
| SCHEMBL1590313 | 0.86 | PTGER4 (0.36) | AKR1C3AKR1C2PTGER4AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | AKR1C3 411/4885AKR1C2 598/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.